Recurrent Respiratory Papillomatosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports
The latest healthcare forecast report provides an in-depth analysis of Recurrent Respiratory Papillomatosis, offering comprehensive insights into the Recurrent Respiratory Papillomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Recurrent Respiratory Papillomatosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Recurrent Respiratory Papillomatosis therapies. Additionally, we cover the landscape of Recurrent Respiratory Papillomatosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Recurrent Respiratory Papillomatosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Recurrent Respiratory Papillomatosis space.
Some of the key facts of the Recurrent Respiratory Papillomatosis Market Report:
The Recurrent Respiratory Papillomatosis market size was valued ~USD 10.26 million in 2023 and is anticipated to grow with a significant CAGR of 39.9% during the study period (2020-2034)
In February 2025, INOVIO (NASDAQ: INO), a biotechnology company focused on developing DNA medicines for HPV-related conditions, cancer, and infectious diseases, announced that peer-reviewed results from its Phase 1/2 trial of INO-3107 for recurrent respiratory papillomatosis (RRP) have been published in Nature Communications. The study, titled DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107, revealed that INO-3107 stimulated new T cell populations in the blood that migrated to the airway and papilloma tissues, correlating with fewer surgeries post-treatment. Of the 32 patients enrolled, 26 (81%) needed fewer surgical interventions after treatment compared to the year before. The therapy was also well tolerated. INOVIO intends to submit a Biologics License Application (BLA) for INO-3107 by mid-2025 and will seek rolling submission and priority review through the FDA's accelerated approval pathway. If approved, INO-3107 would become the first DNA-based medicine approved for any condition in the U.S.
In December 2024, Precigen, Inc. announced that it has completed the submission of its biologics license application (BLA) to the FDA for PRGN-2012 (zopapogene imadenovec†) as a treatment for adult recurrent respiratory papillomatosis (RRP).
In August 2024, Precigen announced a strategic shift to concentrate on the potential commercialization of PRGN-2012. As part of this realignment, the company will reduce its workforce by 20% and halt all preclinical programs. This decision highlights Precigen's dedication to advancing PRGN-2012 and reallocating resources to enhance its commercial potential.
The EU4 and the UK represented about 16% of the 7MM market size, with the RRP market valued at approximately USD 1.66 million in 2023.
In 2023, Germany had the largest market size for RRP among the EU countries, reaching nearly USD 0.45 million, whereas Spain had the smallest market size, approximately USD 0.25 million.
The overall market size of RRP is expected to increase during the forecast period, driven by the anticipated introduction of emerging therapies such as INO-3107, PRGN-2012, and others.
Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others
Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others
The Recurrent Respiratory Papillomatosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Recurrent Respiratory Papillomatosis pipeline products will significantly revolutionize the Recurrent Respiratory Papillomatosis market dynamics.
The total number of diagnosed prevalent cases of RRP in the US was approximately 16,980 in 2023 and is expected to rise during the forecast period.
According to DelveInsight's estimates, the US has the highest number of diagnosed prevalent cases of RRP among the 7MM, followed by the EU4 and the UK, with Japan contributing to 24% and 10% of all RRP cases, respectively.
In 2023, Japan reported the highest number of RRP cases in adults aged 18 and older (~2,400), followed by adolescents aged 9-17 years (~50). The fewest cases were observed in children aged 0-8 years, with a total of approximately 25.
In 2023, the EU4 and the UK reported a total of approximately 6,240 diagnosed prevalent cases of RRP, with around 5,740 cases linked to HPV 6 and/or HPV 11, and about 500 cases associated with other high-risk subtypes such as HPV-16, 18, 31, 33, and 39. The large number of cases related to HPV 6 and 11 highlights the dominant role these strains play in RRP, as they are the primary causative agents.
In 2023, Germany reported the highest number of diagnosed prevalent RRP cases among the EU4 and the UK, with nearly 1,684 cases. France followed with around 1,370 cases, Italy had approximately 1,220, the UK reported about 1,022, and Spain had the lowest with roughly 944 cases. This distribution underscores the differing disease burden across European countries.
Recurrent Respiratory Papillomatosis Overview
Recurrent Respiratory Papillomatosis (RRP) is a rare condition characterized by the growth of benign tumors, called papillomas, in the airways, primarily affecting the larynx, trachea, and bronchi. These growths are caused by infection with the human papillomavirus (HPV), particularly types 6 and 11. RRP can lead to airway obstruction, hoarseness, breathing difficulties, and recurrent infections. The condition is chronic, often requiring repeated surgical interventions to remove the papillomas. It can occur in both children (juvenile-onset RRP) and adults (adult-onset RRP), with varying severity and progression.
Recurrent Respiratory Papillomatosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Recurrent Respiratory Papillomatosis Epidemiology Segmentation:
The Recurrent Respiratory Papillomatosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Recurrent Respiratory Papillomatosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Recurrent Respiratory Papillomatosis market or expected to get launched during the study period. The analysis covers Recurrent Respiratory Papillomatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Recurrent Respiratory Papillomatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Recurrent Respiratory Papillomatosis Market Drivers
Increasing Incidence of HPV Infections
Advancements in Surgical and Therapeutic Options
Rising Awareness and Early Diagnosis
Improved Treatment Modalities
Research and Development Investments
Recurrent Respiratory Papillomatosis Market Barriers
Limited Awareness and Diagnosis
Lack of Cure
High Treatment Costs
Fragmented Treatment Landscape
Limited Availability of Effective Therapies
Challenges in HPV Vaccination Implementation
Scope of the Recurrent Respiratory Papillomatosis Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others
Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others
Recurrent Respiratory Papillomatosis Therapeutic Assessment: Recurrent Respiratory Papillomatosis current marketed and Recurrent Respiratory Papillomatosis emerging therapies
Recurrent Respiratory Papillomatosis Market Dynamics: Recurrent Respiratory Papillomatosis market drivers and Recurrent Respiratory Papillomatosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Recurrent Respiratory Papillomatosis Unmet Needs, KOL's views, Analyst's views, Recurrent Respiratory Papillomatosis Market Access and Reimbursement
Table of Contents
1. Recurrent Respiratory Papillomatosis Market Report Introduction
2. Executive Summary for Recurrent Respiratory Papillomatosis
3. SWOT analysis of Recurrent Respiratory Papillomatosis
4. Recurrent Respiratory Papillomatosis Patient Share (%) Overview at a Glance
5. Recurrent Respiratory Papillomatosis Market Overview at a Glance
6. Recurrent Respiratory Papillomatosis Disease Background and Overview
7. Recurrent Respiratory Papillomatosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Recurrent Respiratory Papillomatosis
9. Recurrent Respiratory Papillomatosis Current Treatment and Medical Practices
10. Recurrent Respiratory Papillomatosis Unmet Needs
11. Recurrent Respiratory Papillomatosis Emerging Therapies
12. Recurrent Respiratory Papillomatosis Market Outlook
13. Country-Wise Recurrent Respiratory Papillomatosis Market Analysis (2020–2034)
14. Recurrent Respiratory Papillomatosis Market Access and Reimbursement of Therapies
15. Recurrent Respiratory Papillomatosis Market Drivers
16. Recurrent Respiratory Papillomatosis Market Barriers
17. Recurrent Respiratory Papillomatosis Appendix
18. Recurrent Respiratory Papillomatosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
8 minutes ago
- CBC
Bills mounting for family of young N.S. woman in ICU after second lung transplant
In the weeks leading up to her daughter's second double lung transplant, Lisa Ali of Cole Harbour, N.S., said she was scared to answer the phone, unsure of who would be on the other end. For more than a year, she and her 20-year-old daughter, Tahlia Ali, had been living in Toronto waiting for the life-saving surgery that is not available in Nova Scotia. That wait comes at an out-of-pocket cost for Nova Scotians — once a patient is put on the transplant list, they must move to Toronto, wait for their match, and stay for months post-surgery to recover. "I was living off my credit card and I had no way to pay it," said Lisa Ali in an interview. "I'm waiting for phone calls for lungs, but the only people that are calling me is creditors." The Alis are one of three Nova Scotia families who have spoken to CBC News in recent months about the financial devastation they have faced while waiting for their loved one to access lung transplant surgery in a different province. The Ali family said a lack of financial support from federal and provincial governments has created an immense strain during an already fraught time. One month after her most recent transplant, Tahlia Ali remains in intensive care. One of the lungs didn't take and had to be removed. "She has a lot of complications from this surgery this time around that we were not expecting," said her grandmother, Judy Robichaud. "We were expecting by this time she'd be out of ICU ... But even the doctors don't know what to expect. They're taking it one day at a time." 1st transplant in 2020 Tahlia Ali was diagnosed with pulmonary hypertension when she was seven. At the time, the family was told the condition was fatal and the only treatment was a lung transplant. She had her first transplant in 2020, when she was 16. Her family was just getting back on their feet in Nova Scotia when she developed new issues, and learned she needed another transplant. "Tahlia, right now, she's fighting," said Robichaud. "We have to go the distance because she is." Adding to the strain is the issue of money. Lisa Ali said most people don't realize that a condition of being on the lung transplant list is to have a full-time caregiver. That person cannot work, as it's their job to get the patient to the hospital for multiple appointments a week, and make sure the patient gets all of their medications. Ali thought she would qualify for employment insurance caregiving benefits when she left her job to go to Toronto, but she was shocked to learn she was less than 10 hours short of qualifying. A statement from Employment and Social Development Canada said she could have appealed that decision, but needed to do so within a 30-day window. Ali said she was overwhelmed, as she had just days to move out of her rental home, find a place to live in Toronto and get to her daughter's first appointment. "I was like, 'I don't have the energy to appeal that,'" she told CBC News. While Nova Scotia offers an allowance of $3,000 a month to families who have to live out of province long term for medical treatment, that only covers the family's rent in Toronto. Ali estimates she's racked up $20,000 in debt covering additional expenses. Now that her granddaughter is facing serious complications, Robichaud expects it will be another year before they get home. She said people have been rallying behind them, offering what they can to help make ends meet. On Saturday, Colleen's Pub in Dartmouth held an event for the family, bringing in more than $5,000. "I don't know how they would be able to manage up there if it wasn't for our family and our friends hanging in there with us and helping to support what's happening right now. I'm just unbelievably grateful for them," Robichaud said. Robichaud and Lisa Ali said both the provincial and federal governments need to do more to help families like theirs, and they plan to work with other Nova Scotia families who are advocating for change. Health Minister Michelle Thompson told CBC News last month that she sympathizes with families who are in similar situations, but said the health-care system is stretched in many directions and the department has to make tough choices. She said Nova Scotia is unique compared to other provinces because it covers some of the travel expenses of the support person who must go with the patient. "We'll continue to review that program, to hear from people. We want to be responsive," Thompson said at the time. "But it isn't a cost-recovery program and we also want to maintain the integrity of the entire system, and I know that's difficult."
CBC
an hour ago
- CBC
No health card, no car, no doctor? No problem for this travelling rural clinic
Pulled into the driveway of a local museum off of a rural road in southwestern Ontario, a 38-foot-long van with decals of cedar trees, a medicine wheel and an 2SLGBTQ flag is parked — ready and waiting for people seeking medical or mental health care. It's a travelling clinic, equipped with mental health staff, a nurse practitioner and in some cases a community paramedic, with the goal of abolishing traditional barriers to health care. No health care card, appointment or payment is needed. The service, aptly named the MobileCare Clinic, recently expanded its schedule to stop throughout rural areas in Chatham-Kent, Ont., based on a needs assessment from local hospitals and 911 calls. It's run primarily through the Canadian Mental Health Association (CMHA) and other community partners. "Our hope is that we are able to address some of the social determinants of health," says Andria Appeldorn, the director of fund development and communications with CMHA Lambton-Kent. She has seen the project manifest from its origin during the pandemic. "We really consider obstacles to care. It could be transportation, it could be reticence to walk into a doctor's office ... thinking about international workers who come into our communities, we're here to serve them as well." On a recent Monday afternoon, the van is at one of its regular stops in North Buxton, a small rural community that was established by escaped African-American enslaved people in the mid-1800s. According to Edna Cornwall Shadd, the staff mental health care coordinator onsite that day, the population is older and might face specific challenges to getting medical or mental health attention. "As a Black woman, it was very important for me to ensure that the communities I identify with were having this type of support available to them, especially in North Buxton," she said. Cornwall Shadd says it's a primary objective of MobileCare to solidify relationships over time, especially when a new community is added to the van's schedule. One recent addition as part of the expansion is Wheatley, Ont. "It's exciting trying to build that relationship [because] there may be some barriers that we ourselves might not even be aware of," she said. "Engagement with the community is really important." For the first time, the MobileCare clinic will also be in North Buxton's community parade, a longstanding heritage celebration called homecoming that draws hundreds into the community. It's something Cornwall Shadd is excited about. "North Buxton in particular is rich in Black history and it's actually quite amazing the number of people even within Chatham-Kent who aren't aware of that," Cornwall Shadd said. "So any way we can help promote the community and that history while also ensuring the population is getting good quality health care is very important." James Bromley, the CMHA's manager of integrated client services, oversees the service, which includes a second bus that services the area of Sarnia-Lambton. He says sometimes it takes a couple of visits for people to understand the breadth of what is available to them through the clinic. "It's a difficult time. There's long wait lists, primary care might not be available in some centres, so [we're] trying to address that, even taking some relief away from our local emergency rooms," he said. Inside the van, three areas are sectioned off. A client is greeted by staff, triaged through an intake form and then seen by professionals. Bromley says some visits are 15 minutes, while others can be up to an hour, addressing everything from wound care to addictions. Three people can be seen at one time on-board. "We can offer referrals, whether for therapy, housing supports, Indigenous supports and even our community paramedic team can arrange home visits [if follow ups are required]." Not every community has the same needs, however. Appeldorn says that the dynamic and needs can change drastically from stop to stop. "Some communities have a lot of seasonal agricultural workers who don't have time to see a family doctor, others have elderly residents who haven't seen a doctor in years. We can really catch things before they become too advanced to be cared for." Other stops on the van's schedule include Walpole Island First Nation, where an Indigenous services team member is added. In urban centres like Chatham, the team includes housing and homelessness support.
CTV News
7 hours ago
- CTV News
B.C. clinicians underscore gaps in menopause care and celebrate recent progress
Clinicians in Canada are calling for a ramping up of care received by patients with menopause. (Getty Images) As millions of Canadians experience menopause, clinicians in B.C. are flagging opportunities to improve the care patients receive. 'I don't think there are enough resources for not only this, but nothing at all,' said Dr. Ana Teresa Armas Enriquez, a physician in Nanaimo. Armas Enriquez owns Women's Vita Medical Clinic, where she prioritizes menopause care. It can take up to six months for someone experiencing symptoms to get in to see her. 'If you wait for a year, you're actually postmenopausal by the time you come see me,' she said. Menopause is when a patient goes 12 months without their period, typically around the age of 50. Some people start experiencing the hallmark symptoms in their mid-30s, during a transitional phase called perimenopause. While mood changes, sleep disturbances, hot flashes, joint paint, vaginal dryness, and dozens of other symptoms present a challenge, Armas Enriquez said medical intervention isn't always required. In the case of one of her patients who spoke with CTV News, it was. 'It really felt like in one day there was a very rapid, massive change,' said Pam Shaw, who started experiencing symptoms a decade ago. Shaw is one of roughly 10 million Canadians – a quarter of the population – over the age of 40 affected by perimenopause, menopause, or post-menopause, according to the Menopause Foundation of Canada. She had hot flashes and insomnia, often waking up 15 times a night. At her job as an instructor at Vancouver Island University, she experienced brain fog and had a hard time keeping up with her 'bright-eyed, bushy-tailed' students. 'In the past, the symptoms of menopause have been treated kind of like a joke – that it's something trivial, not that important, something that women have to endure,' Shaw said. 'I was very fortunate to find a doctor with advanced knowledge on menopausal (and) postmenopausal symptoms and (who) was able to very quickly get me onto a treatment program that worked.' 'Old, outdated information' For the past 10 years, Shaw said her symptoms have been at bay thanks to a low dose of hormone replacement therapy (HRT), which replenishes hormones that decline with age. Kassidy Delcaro, a nurse at Women's Vita Medical Clinic, said some clinicians are reluctant to prescribe HRT. 'There is a lot of very old, outdated information about hormone replacement therapy,' said Delcaro, pointing to old studies that link HRT to a serious cancer risk. The Canadian Cancer Society says the risk is low, and using HRT is a personal decision to be made with a clinician. 'There's definitely safe ways of going about it,' said Delcaro, noting there are various risk assessments to consider before prescribing HRT. 'People who are appropriate providers of menopausal care do know those different guidelines.' Next March, the provincial government said it will start covering the cost of HRT for treating menopause symptoms. For care providers, it's a positive step as conversations about menopause become more common. 'Menopause is definitely having a moment,' said B.C. Women's Health Foundation CEO Cally Wesson. 'Not every woman will have a baby, but every woman will go through menopause.' New clinic a first for Western Canada Wesson, Delcaro, Shaw, and Armas Enriquez agree education about menopause symptoms and treatment options needs to expand. 'A lot of times, we hear stories of women going to their primary care physician and not getting the care that they need,' Wesson said. That's unlikely to happen at the Complex Menopause Clinic in Vancouver, which opened earlier this year. It's the first of its kind in Western Canada, offering specialized care to people with severe symptoms. 'It… could become a standard of care that then other health authorities would adapt,' said Wesson. 'The more we get the right information out, not only to the general community but also to physicians, the better.'
